Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quanterix ( (QTRX) ) just unveiled an announcement.
On June 26, 2025, Quanterix Corporation’s board announced that the 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025. Due to the meeting’s date being more than 30 days from the previous year’s meeting, deadlines for stockholder proposals and nominations have been revised, with new deadlines set for July 11 and July 25, 2025, to comply with SEC rules and the company’s bylaws.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s stock score is primarily impacted by its financial performance challenges, with ongoing losses and negative cash flow being key concerns. Technical analysis provides some short-term optimism, while the valuation remains unattractive due to negative earnings and no dividends. Earnings call insights and corporate events provide some positive strategic outlook, but macroeconomic pressures and revenue declines weigh heavily on the overall score.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix Corporation operates in the biotechnology industry, focusing on developing ultra-sensitive digital immunoassay platforms. These platforms are designed to enable precision health diagnostics, providing critical insights into disease detection and management.
Average Trading Volume: 802,514
Technical Sentiment Signal: Sell
Current Market Cap: $258.4M
See more data about QTRX stock on TipRanks’ Stock Analysis page.